Hospital
Appalachian Regional Healthcare, INC.
Appalachian Regional Healthcare, INC. was paid $38.84M by Medicaid between Jan 2018 and Dec 2024, across 313 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoAPPALACHIAN REGIONAL HEALTHCARE, INC.
MIDDLESBORO, KY 40965
MIDDLESBORO, KY 40965
33aNPI1891792495assigned 06/28/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.84M
24GClaims852,786
24DCodes billed313
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#16 of 36
Median peer was paid$36.08M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HARRIS, HOLLIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 145,053 | $5.45M | |
| 2019 | 121,673 | $6.33M | |
| 2020 | 113,090 | $5.04M | |
| 2021 | 132,278 | $5.49M | |
| 2022 | 115,872 | $5.20M | |
| 2023 | 114,774 | $5.62M | |
| 2024incomplete | 110,046 | $5.71M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 17,302 | 14,532 | $7.37M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.7% | 3,586 | 3,030 | $2.22M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 4,356 | 3,202 | $2.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 2,266 | 1,894 | $1.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.1% | 17,034 | 14,840 | $1.60M |
| G0378 | Hospital observation service, per hour | 4.0% | 4,682 | 2,461 | $1.54M |
| 80053 | Comprehensive metabolic panel | 3.6% | 71,723 | 43,921 | $1.40M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 3,642 | 2,843 | $869K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.8% | 55,090 | 44,391 | $691K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.7% | 1,617 | 966 | $675K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 11,400 | 4,845 | $628K |
| 80061 | Lipid panel | 1.5% | 17,619 | 16,264 | $589K |
301 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 1,896 | $581K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 9,406 | $579K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 11,687 | $524K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 1,456 | $510K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 17,860 | $486K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 5,028 | $400K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 10,393 | $395K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,935 | $377K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,187 | $376K |
| 87631 | <1% | 4,516 | $371K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,578 | $369K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 30,073 | $358K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,855 | $353K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,081 | $340K |
| 36415 | Collection of venous blood by venipuncture | <1% | 111,287 | $299K |
| 83735 | <1% | 9,969 | $287K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,710 | $275K |
| 82607 | <1% | 9,095 | $270K | |
| 82728 | <1% | 7,772 | $260K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,266 | $247K |
| 84439 | <1% | 9,405 | $247K | |
| 84484 | <1% | 8,204 | $243K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,149 | $241K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,146 | $239K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,951 | $238K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,740 | $226K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 217 | $211K |
| 81001 | <1% | 21,340 | $205K | |
| 80074 | <1% | 3,524 | $191K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,977 | $187K |
| 87040 | <1% | 4,124 | $185K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,330 | $179K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,282 | $177K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,557 | $176K |
| 82150 | <1% | 3,694 | $171K | |
| 83690 | <1% | 6,133 | $164K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,237 | $163K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,845 | $153K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 321 | $149K |
| 59025 | Fetal non-stress test | <1% | 2,793 | $146K |
| 83540 | <1% | 7,295 | $144K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,042 | $137K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,734 | $136K |
| 74022 | <1% | 1,307 | $131K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,018 | $126K |
| 81025 | <1% | 5,366 | $120K | |
| 83550 | <1% | 6,555 | $118K | |
| 82746 | <1% | 2,946 | $112K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,177 | $110K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,841 | $110K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,889 | $109K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,717 | $102K |
| 83880 | <1% | 2,794 | $97K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,935 | $95K |
| 72100 | <1% | 2,255 | $94K | |
| 85730 | <1% | 3,075 | $91K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 344 | $88K |
| 73630 | <1% | 1,757 | $87K | |
| 73030 | <1% | 2,075 | $81K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,828 | $81K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,601 | $78K |
| 73610 | <1% | 1,580 | $77K | |
| 84702 | <1% | 2,646 | $77K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,450 | $76K |
| 86038 | <1% | 2,151 | $75K | |
| 85610 | <1% | 5,357 | $74K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 363 | $73K |
| 96376 | <1% | 1,866 | $71K | |
| 73130 | <1% | 1,474 | $70K | |
| 82553 | <1% | 2,732 | $66K | |
| 73110 | <1% | 1,271 | $65K | |
| 87186 | <1% | 2,381 | $63K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,697 | $61K |
| 83605 | <1% | 2,816 | $60K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,685 | $53K |
| 20610 | <1% | 2,878 | $52K | |
| 84403 | <1% | 1,641 | $50K | |
| 82570 | <1% | 1,493 | $49K | |
| 96367 | <1% | 836 | $49K | |
| 71250 | <1% | 209 | $46K | |
| 82550 | <1% | 3,481 | $44K | |
| 87077 | <1% | 3,660 | $43K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 863 | $43K |
| 93041 | <1% | 1,969 | $42K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,179 | $42K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 146 | $41K |
| 74018 | <1% | 817 | $41K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 81 | $41K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,928 | $40K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 249 | $40K |
| 83001 | <1% | 902 | $40K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,971 | $39K |
| 83525 | <1% | 1,466 | $37K | |
| 82803 | <1% | 1,114 | $37K | |
| 73562 | <1% | 755 | $36K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 464 | $36K |
| 85378 | <1% | 1,764 | $35K | |
| 84703 | <1% | 2,028 | $35K | |
| 86140 | <1% | 2,370 | $34K | |
| 87070 | <1% | 1,723 | $34K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,420 | $33K |
| 93225 | <1% | 700 | $32K | |
| 73564 | <1% | 626 | $32K | |
| 82043 | <1% | 3,085 | $32K | |
| 86787 | <1% | 668 | $32K | |
| 83002 | <1% | 709 | $31K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,440 | $30K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 23 | $29K |
| 97162 | <1% | 759 | $29K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,146 | $28K |
| 86431 | <1% | 1,112 | $27K | |
| 87581 | <1% | 327 | $27K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 53 | $27K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,074 | $26K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,212 | $26K |
| 93226 | <1% | 358 | $26K | |
| 0100U | <1% | 388 | $25K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,049 | $24K |
| 76536 | <1% | 269 | $24K | |
| 87590 | <1% | 1,462 | $24K | |
| 87480 | <1% | 2,211 | $23K | |
| 86901 | <1% | 1,574 | $23K | |
| 93017 | <1% | 268 | $23K | |
| 80076 | <1% | 873 | $22K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 43 | $22K |
| 72141 | <1% | 44 | $21K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 555 | $20K |
| 87510 | <1% | 1,966 | $20K | |
| 87076 | <1% | 2,430 | $19K | |
| 72084 | <1% | 155 | $19K | |
| 74178 | <1% | 14 | $19K | |
| 87660 | <1% | 1,966 | $19K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,212 | $18K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 40 | $17K |
| 87486 | <1% | 343 | $17K | |
| 72040 | <1% | 388 | $17K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 162 | $16K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,686 | $16K |
| 84550 | <1% | 1,693 | $15K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 223 | $15K |
| 73502 | <1% | 391 | $15K | |
| 84270 | <1% | 757 | $15K | |
| 86592 | <1% | 1,451 | $15K | |
| 86200 | <1% | 784 | $15K | |
| 84481 | <1% | 282 | $14K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 33 | $14K |
| 73560 | <1% | 364 | $14K | |
| 86900 | <1% | 1,814 | $14K | |
| 83516 | <1% | 267 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $13K |
| 82565 | <1% | 1,045 | $13K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,081 | $12K |
| 82947 | <1% | 802 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 921 | $12K |
| 36600 | <1% | 1,187 | $11K | |
| 83655 | <1% | 380 | $11K | |
| 86850 | <1% | 1,230 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,691 | $10K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 116 | $10K |
| 84402 | <1% | 724 | $10K | |
| 86762 | <1% | 551 | $10K | |
| 97597 | <1% | 212 | $9K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $9K |
| 72110 | <1% | 176 | $9K | |
| 81002 | <1% | 1,479 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 460 | $8K |
| 82670 | <1% | 228 | $8K | |
| 93971 | <1% | 79 | $8K | |
| 97014 | <1% | 215 | $7K | |
| 82105 | <1% | 284 | $7K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 221 | $7K |
| 84144 | <1% | 194 | $7K | |
| 82652 | <1% | 262 | $7K | |
| 80081 | <1% | 77 | $7K | |
| 73221 | <1% | 16 | $6K | |
| J3490 | Unclassified drugs | <1% | 2,014 | $6K |
| 84436 | <1% | 166 | $6K | |
| 0012A | <1% | 591 | $6K | |
| 82626 | <1% | 151 | $6K | |
| 72050 | <1% | 86 | $6K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 89 | $5K |
| 84520 | <1% | 491 | $5K | |
| 90715 | <1% | 171 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 457 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,695 | $5K |
| 86756 | <1% | 187 | $5K | |
| 88142 | <1% | 242 | $5K | |
| 76642 | <1% | 106 | $5K | |
| 77080 | <1% | 106 | $5K | |
| 82962 | <1% | 1,955 | $5K | |
| 76775 | <1% | 44 | $4K | |
| 85379 | <1% | 183 | $4K | |
| 0011A | <1% | 594 | $4K | |
| 83921 | <1% | 74 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 18 | $4K |
| 86696 | <1% | 153 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $4K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 188 | $4K |
| 84146 | <1% | 100 | $4K | |
| 17110 | <1% | 129 | $4K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 42 | $4K |
| 87449 | <1% | 80 | $4K | |
| 86376 | <1% | 234 | $4K | |
| 86695 | <1% | 129 | $4K | |
| 85027 | <1% | 322 | $3K | |
| 85652 | <1% | 2,278 | $3K | |
| 85651 | <1% | 358 | $3K | |
| 78227 | <1% | 14 | $3K | |
| 81003 | <1% | 1,087 | $3K | |
| 87653 | <1% | 165 | $3K | |
| 82247 | <1% | 202 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,036 | $3K |
| 82977 | <1% | 201 | $3K | |
| 99499 | <1% | 65 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,258 | $3K |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 219 | $3K |
| 73080 | <1% | 64 | $3K | |
| 0001A | <1% | 144 | $2K | |
| 74019 | <1% | 28 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $2K |
| 88185 | <1% | 37 | $2K | |
| 84153 | <1% | 72 | $2K | |
| 0002A | <1% | 128 | $2K | |
| 85018 | <1% | 223 | $2K | |
| 85014 | <1% | 217 | $2K | |
| 80299 | <1% | 15 | $2K | |
| 36416 | <1% | 566 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 483 | $2K |
| 84630 | <1% | 70 | $2K | |
| 73090 | <1% | 37 | $2K | |
| 86703 | <1% | 120 | $2K | |
| 87634 | <1% | 42 | $2K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 114 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 833 | $1K |
| 86235 | <1% | 13 | $1K | |
| 93880 | <1% | 18 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 272 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,645 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 133 | $1K |
| 51798 | <1% | 173 | $1K | |
| 86706 | <1% | 38 | $1K | |
| 94060 | <1% | 14 | $1K | |
| 93224 | <1% | 29 | $1K | |
| 87081 | <1% | 59 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 81 | $1K |
| 76770 | <1% | 15 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 30 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,084 | $995.67 |
| 71101 | <1% | 14 | $891.98 | |
| 73590 | <1% | 16 | $888.75 | |
| 82248 | <1% | 62 | $881.68 | |
| 83883 | <1% | 14 | $871.75 | |
| 0064A | <1% | 123 | $871.53 | |
| 0097U | <1% | 18 | $865.86 | |
| 12001 | <1% | 12 | $861.92 | |
| 86225 | <1% | 27 | $817.11 | |
| 82140 | <1% | 29 | $774.06 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 371 | $766.19 |
| 96368 | <1% | 18 | $754.59 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 147 | $700.25 |
| 88304 | <1% | 32 | $612.24 | |
| 82103 | <1% | 15 | $592.06 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 33 | $583.13 |
| 87507 | <1% | 13 | $491.40 | |
| 82272 | <1% | 147 | $470.97 | |
| 85660 | <1% | 37 | $447.15 | |
| 87340 | <1% | 13 | $424.07 | |
| 51702 | <1% | 14 | $414.27 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 48 | $385.24 |
| 90714 | <1% | 13 | $354.74 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 12 | $322.56 |
| 73565 | <1% | 14 | $302.02 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 17 | $300.02 |
| 82677 | <1% | 12 | $297.06 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 17 | $291.14 |
| 90662 | <1% | 17 | $286.97 | |
| A9270 | Non-covered item or service | <1% | 1,352 | $264.33 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 17 | $261.84 |
| 86803 | <1% | 13 | $258.72 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 86 | $217.91 |
| 99406 | <1% | 13 | $214.76 | |
| 0031A | <1% | 13 | $203.92 | |
| 84156 | <1% | 13 | $203.87 | |
| 80143 | <1% | 14 | $157.68 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 18 | $149.47 |
| 80050 | General health panel | <1% | 13 | $133.38 |
| 87802 | <1% | 16 | $122.76 | |
| 84100 | <1% | 15 | $118.33 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 105 | $106.38 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 127 | $88.88 |
| 86336 | <1% | 12 | $60.47 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 22 | $41.99 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 37 | $37.01 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 29 | $31.98 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 15 | $15.72 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 17 | $14.88 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 14 | $13.58 |
| 84479 | <1% | 30 | $7.18 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 21 | $0.02 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | 0% | 70 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, HOLLIE (PRESIDENT AND CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.